...
首页> 外文期刊>Current pharmaceutical design >Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy of biologics including prebiotics and probiotics.
【24h】

Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy of biologics including prebiotics and probiotics.

机译:在动物模型和人类中进行非侵入性测试:一种评估包括益生元和益生菌在内的生物制剂功效的新范例。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Newer biological agents that are designed to have multiple effects on a host require better ways to determine both their safety and toxicity. Indeed ecologically potent factors such as agents that can alter the gut milieu and change host responses are now being realized as a viable alternative to more focused pharmaceuticals. Even in the pharmaceutical arena there is a growing awareness of the preventative and therapeutic potential of alternative agents. Probiotics and prebiotics amongst other agents fall into this category and can have both direct and indirect effects on the pathogenesis and progress of disease. This review details some of the new approaches using non-invasive tests to enable firstly a better definition of a stressed through to a damaged gastrointestinal mucosa. They constitute ways to apply dynamic function testing in animal models and humans to provide reference points to which other measurements can be related e.g. altered circulating cytokines, altered gene expression. As such this phenotypic scaffold, alone and combined with newer molecular parameters, will improve our understanding of the interaction of luminal factors within the alimentary tract and the impact that these have on physiologically challenged mucosa and in disease both at the gastrointestinal level and also in remote organs. Practically, the dynamic function tests, primarily breath tests, can now be used as diagnostic and prognostic indicators of the efficacy of new biologics such as probiotics and prebiotics that in part elicit their effects by altering the ecology of particular regions of the intestine.
机译:旨在对宿主产生多种作用的新型生物制剂需要更好的方法来确定其安全性和毒性。实际上,如今已经认识到具有生态影响力的因素,例如可以改变肠道环境和改变宿主反应的药物,是更集中的药物的可行替代品。即使在制药领域,人们也越来越意识到替代药物的预防和治疗潜力。益生菌和益生元以及其他药物均属于此类,并且可以对疾病的发病机理和进展产生直接或间接的影响。这篇综述详细介绍了一些使用非侵入性测试的新方法,以首先更好地定义从压力到受损肠胃黏膜的压力。它们构成在动物模型和人类中应用动态功能测试的方法,以提供其他测量可与之相关的参考点,例如:改变循环细胞因子,改变基因表达。因此,这种表型支架单独使用,并与较新的分子参数结合使用,将使我们更好地理解消化道内腔内因子的相互作用以及这些因子对胃肠道及远处的生理性粘膜和疾病的影响。器官。实际上,动态功能测试(主要是呼气测试)现在可以用作新生物制剂(如益生菌和益生元)功效的诊断和预后指标,这些生物制剂在一定程度上通过改变肠道特定区域的生态来发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号